Latest Regenerative Ophthalmology News

Pluri Helping Placenta-Derived Collagen Company Scale Up Production in Europe

Resbiomed, a placental collagen materials manufacturer, is working on scaling up production for what appears regenerative ophthalmology in Europe.

Manufacturing, Ophthalmology

January 24, 2026

BlueRock Cell Therapeutics Receives FDA Orphan Drug for its Ocular Stem Cell Therapy, OpCT-001

OpCT-001 is an iPSC-derived cell therapy for retinitis pigmentosa, and it's now entering clinical testing following Orphan Drug status.

iPSC, Ophthalmology, Regulatory

January 22, 2026

Celularity to License its Amniotic Biologics to Opthalmic Startup DefEYE

Celularity and DefEYE’s agreement aims to accelerate the development and commercialization of advanced regenerative biologic solutions for ophthalmic care.

Ophthalmology

December 14, 2025

Neuroprotective Effects of SIRT1 Gene Therapy Protects Stem Cell-Derived Retinal Ganglion Cells from Oxidative Stress

Researchers are exploring whether SIRT1 gene therapy can protect human retinal cells from damage linked to optic neuropathies.

Gene Therapy, Ophthalmology

July 23, 2025

Stem Cell Trial: BlueRock Launches Study of iPSC-Derived Photoreceptor Cell Therapy for Inherited Retinal Diseases

The trial will test whether lab-grown photoreceptor cells can be safely transplanted to help people with inherited vision loss.

iPSC, Ophthalmology

July 20, 2025

BlueRock Therapeutics Begins Phase 1/2a Trial of Stem Cell Therapy OpCT-001 for Retinal Diseases

The Bayer owned company just starting dosing patients with OpCT-001, an iPSC-derived cell therapy aiming to restore vision in inherited retinal diseases.

iPSC, Ophthalmology

July 11, 2025

Bayer’s BlueRock Therapeutics receives FDA Fast Track Designation for its iPSC OpCT-001 for primary photoreceptor diseases

This milestone positions BlueRock Therapeutics to accelerate clinical development of OpCT-001, aiming to restore vision in patients facing irreversible blindness.

iPSC, Ophthalmology

April 14, 2025

Luxa Biotechnology Reports Significant Results in Dry Age-Related Macular Degeneration Stem Cell Trial

Ophthalmology

March 15, 2025

Study: Mass General successfully restores corneas with patients’ own stem cells

Ophthalmology

March 5, 2025

Pandorum teams up with AGC Biologics to make stem cell exosomes for Ulcerative Corneal Blindness

Exosomes/Extracellular Vesicles, Manufacturing, Ophthalmology

March 3, 2025